Manimtim W M, Hasday J D, Hester L, Fairchild K D, Lovchik J C, Viscardi R M
Departments of Pediatrics, University of Maryland School of Medicine, Baltimore 21201, USA.
Infect Immun. 2001 Jun;69(6):3906-15. doi: 10.1128/IAI.69.6.3906-3915.2001.
We previously observed that Ureaplasma urealyticum respiratory tract colonization in infants with a birth weight of < or =1,250 g was associated with increases in the tracheal aspirate proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin-8 (IL-8) relative to the counterregulatory cytokine IL-6 during the first week of life (A. M. Patterson, V. Taciak, J. Lovchik, R. E. Fox, A. B. Campbell, and R. M. Viscardi, Pediatr. Infect. Dis. J. 17:321-328, 1998). We hypothesized that U. urealyticum alters the host immune response in the presence of a coinflammatory stimulus (e.g., bacterial infection or hyperoxia) by shifting the balance of cytokine expression towards the proinflammatory cytokines. To test this hypothesis, we compared the release of TNF-alpha, IL-8, IL-6, and IL-10 in vitro by unstimulated and U. urealyticum (with or without lipopolysaccharide [LPS])-stimulated human monocytes from adult peripheral blood and from term and preterm cord blood. U. urealyticum alone and in combination with LPS induced concentration- and development-dependent changes in cytokine release. In vitro inoculation with low-inoculum U. urealyticum (10(3) color-changing units [CCU]) (i) partially blocked the LPS-stimulated IL-6 release by all cells and reduced LPS-stimulated IL-10 release by preterm cells, (ii) stimulated TNF-alpha and IL-8 release by preterm cells, and (iii) augmented LPS-stimulated TNF-alpha release in all cells. In preterm cells, high-inoculum U. urealyticum (10(6) CCU) (i) stimulated TNF-alpha and IL-8, but not IL-6 or IL-10, release and (ii) augmented LPS-stimulated TNF-alpha and IL-8 release. High-inoculum U. urealyticum (i) stimulated release of all four cytokines in term cells and IL-8 release in adult cells and (ii) augmented LPS-induced TNF-alpha, IL-10, and IL-8 release in term cells but did not significantly affect LPS-induced cytokine release in adult cells. We speculate that U. urealyticum enhances the proinflammatory response to a second infection by blocking expression of counterregulatory cytokines (IL-6 and IL-10), predisposing the preterm infant to prolonged and dysregulated inflammation, lung injury, and impaired clearance of secondary infections.
我们之前观察到,出生体重≤1250g的婴儿解脲脲原体呼吸道定植与出生后第一周气管吸出物中促炎细胞因子肿瘤坏死因子α(TNF-α)和白细胞介素-8(IL-8)相对于调节性细胞因子白细胞介素-6(IL-6)的增加有关(A.M. 帕特森、V. 塔恰克、J. 洛夫奇克、R.E. 福克斯、A.B. 坎贝尔和R.M. 维斯卡迪,《儿科传染病杂志》17:321 - 328,1998年)。我们假设,解脲脲原体在存在共刺激炎症(如细菌感染或高氧)的情况下,通过将细胞因子表达平衡转向促炎细胞因子来改变宿主免疫反应。为了验证这一假设,我们比较了未刺激的以及经解脲脲原体(有或无脂多糖[LPS])刺激的来自成人外周血、足月和早产脐带血的人单核细胞体外释放TNF-α、IL-8、IL-6和IL-10的情况。单独的解脲脲原体以及与LPS联合使用均诱导了细胞因子释放的浓度和发育依赖性变化。用低接种量的解脲脲原体(10³ 颜色改变单位[CCU])进行体外接种,(i)部分阻断了所有细胞LPS刺激的IL-6释放,并降低了早产细胞LPS刺激的IL-10释放,(ii)刺激了早产细胞释放TNF-α和IL-8,以及(iii)增强了所有细胞LPS刺激的TNF-α释放。在早产细胞中,高接种量的解脲脲原体(10⁶ CCU)(i)刺激了TNF-α和IL-8的释放,但未刺激IL-6或IL-10的释放,以及(ii)增强了LPS刺激的TNF-α和IL-8释放。高接种量的解脲脲原体(i)刺激了足月细胞中所有四种细胞因子的释放以及成人细胞中IL-8的释放,以及(ii)增强了足月细胞中LPS诱导的TNF-α、IL-10和IL-8释放,但对成人细胞中LPS诱导的细胞因子释放没有显著影响。我们推测,解脲脲原体通过阻断调节性细胞因子(IL-6和IL-10)的表达来增强对二次感染的促炎反应,使早产婴儿易发生持续且失调的炎症、肺损伤以及二次感染清除受损。